ChemGenex Pharmaceuticals Receives Orphan Drug Status for Ceflatonin in the United States and Europe

Strategic Insights -

ChemGenex Pharmaceuticals has been granted orphan drug status for its most advanced drug, Ceflatonin, by the U.S. Food & Drug Administration (FDA) and the European Union for the treatment of chronic myeloid leukemia (CML). This designation provides ChemGenex with market exclusivity, protocol assistance, and reduced fees for the development of Ceflatonin. Ceflatonin is a novel drug that induces apoptosis and inhibits angiogenesis, and is currently being evaluated in clinical trials for the treatment of CML, myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML).

Key Takeaways:

  • The FDA has granted orphan drug status to Ceflatonin for the treatment of CML, providing 7 years of market exclusivity.
  • The European Union has also granted orphan status to Ceflatonin for the treatment of AML, providing similar advantages.
  • Ceflatonin is a novel drug that induces apoptosis and inhibits angiogenesis, with ongoing clinical trials evaluating its efficacy and safety.
  • ChemGenex Pharmaceuticals is dedicated to developing therapeutics in oncology, diabetes, obesity, and depression.
  • Clinical trials for Ceflatonin are scheduled to begin in Q2, 2006, with centers in the United States, Germany, France, and Italy.
  • Ceflatonin is not approved by the FDA as a treatment in any indication and is currently being evaluated for future regulatory applications.

Statistics:

  • The FDA has granted 7 years of market exclusivity to Ceflatonin for the treatment of CML.
  • The European Union has granted similar advantages to Ceflatonin for the treatment of AML.
  • ChemGenex Pharmaceuticals is currently underway with clinical trials for Ceflatonin, with 2 upcoming studies in CML patients harboring the T315I point mutation.
  • The multinational phase II/III study in CML patients will be conducted in the United States, Germany, France, and Italy.
  • ChemGenex Pharmaceuticals is a pharmaceutical development company with a focus on oncology, diabetes, obesity, and depression.

Sources:

  • World Disease Weekly
  • NewsRx.com
  • FDA (U.S. Food & Drug Administration)
  • European Medicines Agency (EMEA)
  • Committee for Orphan Medicinal Products (COMP)